Abstract

Oral morphine is the standard analgesic for severe opioid-responsive cancer pain.¹ It is traditionally used as an aqueous solution, prepared as needed by the hospital or community pharmacy, and although slow-release morphine sulphate tablets (MST-Continus) are now widely used many doctors still prescribe an aqueous solution for initial dose titration, for top-up use, “as needed” use and for patients who dislike tablets.²